Clinical Trials for High Risk Smoldering Myeloma Patients
Be proactive in your care by learning about what clinical trials are available to you. No matter where you are in the precursor journey, learning about these trials now can help prepare you for what might come in your future. Multiple Myeloma Specialist, Dr. Jeffrey Zonder, will share his experience in high-risk clinical trials and explain their importance in the future of myeloma.
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Jeffrey Zonder, M.D.
Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute (KCI) and Wayne State University School of Medicine. He is the leader of the KCI Multiple Myeloma and Amyloidosis Multidisciplinary Team and co-leader of Molecular Therapeutic Program. He is e member of the Steering Committee at the Multiple Myeloma Research Consortium, a medical advisor for the Amyloidosis Support Group Networks, and a member of the International Myeloma Working Group, the International Myeloma Society and the International Amyloidosis Society. He is a member of the Southwest Oncology Group’s (SWOG) Barlogie-Salmon Myeloma Committee. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis. He completed a fellowship in hematology-oncology at Wayne State University and his medical residency at the University of Rochester, New York. He received his medical degree from Wayne State University School of Medicine.